Oncaspar pegaspargase regulatory update

EMA’s CHMP recommended approval of Oncaspar pegaspargase from Baxalta to treat acute lymphoblastic leukemia (ALL) in patients of all ages in combination with antineoplastic therapy. In July, Baxalta p...